Fortress Biotech Inc

Fortress Biotech CFO’s recent ESPP purchase signals confidence; insider buying amid volatility, clinical milestones, and $205 M funding may boost future value.

Fortress Biotech insiders buy shares at $3.10, signaling confidence ahead of potential FDA approvals, partnership deals, and value‑based reimbursement opportunities.